A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies
Sign Up to like & getrecommendations! Published in 2021 at "Scientific Reports"
DOI: 10.1038/s41598-021-01707-3
Abstract: WT2725 is a Wilms’ tumor gene 1 (WT1)-derived-oligopeptide vaccine designed to induce WT1-specific cytotoxic T-lymphocytes against WT1+ tumors in human leukocyte antigen (HLA)-A*0201+ and/or HLA-A*0206+ patients. Here, we report the results of a phase I… read more here.
Keywords: dosing emulsion; patients advanced; wt2725 dosing; phase study ... See more keywords